Fig. 2From: A randomized phase II trial evaluating the addition of low dose, short course sunitinib to docetaxel in advanced solid tumoursProgression-free survival 2a Progression-free survival in the overall patient population 2b Progression-free survival in the breast cancer subgroup 2c Progression-free survival in the lung cancer subgroup 2d Progression-free survival in the other cancers subgroupBack to article page